108605
论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
- 3.4 Breast Cancer (Dove Med Press)
- 3.2 Clin Epidemiol
- 2.6 Cancer Manag Res
- 2.9 Infect Drug Resist
- 3.7 Clin Interv Aging
- 5.1 Drug Des Dev Ther
- 3.1 Int J Chronic Obstr
- 6.6 Int J Nanomed
- 2.6 Int J Women's Health
- 2.9 Neuropsych Dis Treat
- 2.8 OncoTargets Ther
- 2.0 Patient Prefer Adher
- 2.2 Ther Clin Risk Manag
- 2.5 J Pain Res
- 3.0 Diabet Metab Synd Ob
- 3.2 Psychol Res Behav Ma
- 3.4 Nat Sci Sleep
- 1.8 Pharmgenomics Pers Med
- 2.0 Risk Manag Healthc Policy
- 4.1 J Inflamm Res
- 2.0 Int J Gen Med
- 3.4 J Hepatocell Carcinoma
- 3.0 J Asthma Allergy
- 2.2 Clin Cosmet Investig Dermatol
- 2.4 J Multidiscip Healthc
已发表论文
TP53 突变在黏液性交界性卵巢肿瘤恶性进展中的作用：一例病例报告及文献综述
Authors Liang M, Xie S, Chua KJC, Saunders A, Deng X, Tong C, Lai J, Chien J, Zeng S
Received 14 March 2025
Accepted for publication 23 May 2025
Published 23 September 2025 Volume 2025:17 Pages 3155—3165
DOI https://doi.org/10.2147/IJWH.S523782
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 2
Editor who approved publication: Dr Matteo Frigerio
Meirong Liang,1,2,* Sijun Xie,1,* Katherine Jane Chung Chua,3 Anais Saunders,2 Xuqing Deng,1 Caili Tong,2 Jinping Lai,4 Jeremy Chien,2,3 Siyuan Zeng1
1Department of Gynecological Oncology, Jiangxi Maternal and Child Health Hospital, Nanchang, Jiangxi, People’s Republic of China; 2Department of Biochemistry and Molecular Medicine, University of California, Davis. Sacramento, CA, USA; 3Department of Obstetrics and Gynecology, University of California, Davis, Sacramento, CA, USA; 4Department of Pathology and Laboratory Medicine, Kaiser Permanente Sacramento Medical Center, Sacramento, CA, USA
*These authors contributed equally to this work
Correspondence: Siyuan Zeng, Department of Gynecological Oncology, Jiangxi Maternal and Child Health Hospital, No. 508, West Station Street, Jiulonghu Management Office, Honggutan District, Nanchang, Jiangxi, People’s Republic of China, Email jacksonzeng@yeah.net Meirong Liang, Department of Gynecological Oncology, Jiangxi Maternal and Child Health Hospital, No. 318, Bayi Avenue, Donghu District, Nanchang, Jiangxi, People’s Republic of China, Email lmr1013@126.com
Background: Mucinous ovarian carcinoma (MOC) is characterized by aggressive behavior and limited responsiveness to standard chemotherapeutic regimens. The infrequent occurrence of MOC arising from mucinous borderline ovarian tumors (MBOTs) and the lack of readily identifiable diagnostic markers pose significant challenges to the development of effective treatment strategies. This report presents a case of a 26-year-old woman with MBOT progression to metastatic MOC despite aggressive surgical intervention and adjuvant chemotherapy, aiming to identify potential diagnostic and therapeutic improvements.
Results: A review of the literature revealed fewer than 30 comparable cases, underscoring the absence of established guidelines for diagnosing and treating the progression of MBOT to invasive MOC, particularly with respect to the role of TP53 mutations. In our patient’s case, we observed some changes in immunohistochemical marker expression between the MBOT and the subsequent invasive MOC, including altered p53 expression. Although these changes, considered in the context of existing literature, hint at a complex transformation process potentially involving genetic and epigenetic alterations, including TP53 mutations, further detailed genomic or transcriptomic analyses would be required to confirm this in our specific case. The diagnostic process was further complicated by clinical and pathological similarities with gastrointestinal malignancies. Ultimately, disease progression necessitated adjustments to the treatment plan, despite the use of a multi-agent chemotherapy regimen consisting of paclitaxel, carboplatin, and bevacizumab.
Conclusion: The transition from MBOT to MOC is characterized by intricate genetic and epigenetic alterations, especially involving TP53 mutations. This progression presents considerable diagnostic challenges due to similarities with gastrointestinal cancers. Therefore, given the strong correlation between TP53 mutations and chemoresistance, there is a pressing need to develop targeted therapies and enhance diagnostic strategies.
Keywords: mucinous borderline ovarian tumors, mucinous ovarian carcinoma, TP53 mutations, chemotherapy, targeted therapy
1Department of Gynecological Oncology, Jiangxi Maternal and Child Health Hospital, Nanchang, Jiangxi, People’s Republic of China; 2Department of Biochemistry and Molecular Medicine, University of California, Davis. Sacramento, CA, USA; 3Department of Obstetrics and Gynecology, University of California, Davis, Sacramento, CA, USA; 4Department of Pathology and Laboratory Medicine, Kaiser Permanente Sacramento Medical Center, Sacramento, CA, USA
*These authors contributed equally to this work
Correspondence: Siyuan Zeng, Department of Gynecological Oncology, Jiangxi Maternal and Child Health Hospital, No. 508, West Station Street, Jiulonghu Management Office, Honggutan District, Nanchang, Jiangxi, People’s Republic of China, Email jacksonzeng@yeah.net Meirong Liang, Department of Gynecological Oncology, Jiangxi Maternal and Child Health Hospital, No. 318, Bayi Avenue, Donghu District, Nanchang, Jiangxi, People’s Republic of China, Email lmr1013@126.com
Background: Mucinous ovarian carcinoma (MOC) is characterized by aggressive behavior and limited responsiveness to standard chemotherapeutic regimens. The infrequent occurrence of MOC arising from mucinous borderline ovarian tumors (MBOTs) and the lack of readily identifiable diagnostic markers pose significant challenges to the development of effective treatment strategies. This report presents a case of a 26-year-old woman with MBOT progression to metastatic MOC despite aggressive surgical intervention and adjuvant chemotherapy, aiming to identify potential diagnostic and therapeutic improvements.
Results: A review of the literature revealed fewer than 30 comparable cases, underscoring the absence of established guidelines for diagnosing and treating the progression of MBOT to invasive MOC, particularly with respect to the role of TP53 mutations. In our patient’s case, we observed some changes in immunohistochemical marker expression between the MBOT and the subsequent invasive MOC, including altered p53 expression. Although these changes, considered in the context of existing literature, hint at a complex transformation process potentially involving genetic and epigenetic alterations, including TP53 mutations, further detailed genomic or transcriptomic analyses would be required to confirm this in our specific case. The diagnostic process was further complicated by clinical and pathological similarities with gastrointestinal malignancies. Ultimately, disease progression necessitated adjustments to the treatment plan, despite the use of a multi-agent chemotherapy regimen consisting of paclitaxel, carboplatin, and bevacizumab.
Conclusion: The transition from MBOT to MOC is characterized by intricate genetic and epigenetic alterations, especially involving TP53 mutations. This progression presents considerable diagnostic challenges due to similarities with gastrointestinal cancers. Therefore, given the strong correlation between TP53 mutations and chemoresistance, there is a pressing need to develop targeted therapies and enhance diagnostic strategies.
Keywords: mucinous borderline ovarian tumors, mucinous ovarian carcinoma, TP53 mutations, chemotherapy, targeted therapy